Evidence map›Paper›PMID 24236294›Full record

Trial reportBioMed research international2013

Is delayed pressure urticaria associated with increased systemic release of sCD40L?

T Jasinska, A Grzanka, E Machura, A Kasperska-Zajac

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

T JasinskaChair and Clinical Department of Internal Diseases, Dermatology and Allergology ul. M. Curie-Skłodowskiej 10, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland.
A Grzanka
E Machura
A Kasperska-Zajac

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated levels of soluble CD40 Ligand (sCD40L) were found in serum but not in plasma of patients with chronic spontaneous urticaria (CU). What is important is that sCD40L has proinflammatory properties, and its elevated plasma level may indicate increased risk of cardiovascular events. These observations should stimulate further evaluation of sCD40L in different forms of urticaria.

aimIn the present study, sCD40L plasma level was investigated in delayed pressure urticaria (DPU).

methodsAs platelets are predominant and variable sources of sCD40L, we investigated sCD40L concentration in platelet-poor plasma (PPP), which seems the best way to minimize the potential contribution of these cells to the ligand level.

resultsPlasma sCD40L concentration was significantly increased in the DPU group compared to the healthy controls.

conclusionsIt seems that DPU is associated with increased systemic release of sCD40L, which is believed to derive predominantly from activated platelets. The present study as well as the earlier contributions suggest that distinct cells activity, including platelets, may be identified in different types of urticaria.

Indexed as

Platelet ActivationAdultBlood PlateletsCD40 LigandFemaleHumansMaleUrticariaCD40 Ligand

Identifiers

PMID24236294
PMCPMC3819883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.